Literature DB >> 23149281

Bipolar disorder: the shift to overdiagnosis.

Philip B Mitchell1.   

Abstract

Sometimes dramatically changing vogues in diagnostic practice in psychiatry resemble the volatility of international share markets. One such quickly shifting diagnostic area has been that of bipolar disorder (BD). Historically regarded as a relatively uncommon condition until recent decades, the construct of BD underwent a major expansion in the 1990s and 2000s with promulgation of the concept of the soft bipolar spectrum disorder, from which the recent research focus on subthreshold BD presentations was derived. Related to this has been renewed interest in treatments for BD from the pharmaceutical industry. The increasing rates of diagnosis have largely related to BD II, for which there has been a dramatic broadening of diagnostic criteria. This article critically reviews research data, both for broadening the diagnostic criteria for BD and, conversely, for the growing evidence of overdiagnosis in clinical practice. Why does this debate matter? I would suggest that there are many valid reasons to be concerned about overdiagnosis: first, the potential for overtreatment or inappropriate treatment of such patients with mood stabilizing treatments, including antipsychotics; second, the potential for diagnostic oversimplification, with consequent diagnostic deskilling and loss of credibility for the psychiatric profession; and third, the potential major impact on etiologic research for this condition. Psychiatry should not uncritically accept the shift to overdiagnosis, which has developed a rapid momentum in recent decades, in both clinical and academic circles. We must ensure, as a profession, that any change in diagnostic practice is underpinned by rigorous and critical research inquiry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149281     DOI: 10.1177/070674371205701103

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  8 in total

1.  Positive and Negative Activation in the Mood Disorder Questionnaire: Associations With Psychopathology and Emotion Dysregulation in a Clinical Sample.

Authors:  Ryan W Carpenter; Kasey Stanton; Noah N Emery; Mark Zimmerman
Journal:  Assessment       Date:  2019-05-29

Review 2.  Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence.

Authors:  Anne Duffy
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

3.  Under-diagnosis of mood disorders in Canada.

Authors:  L Pelletier; S O'Donnell; J Dykxhoorn; L McRae; S B Patten
Journal:  Epidemiol Psychiatr Sci       Date:  2016-05-06       Impact factor: 6.892

4.  Comparison of the estimated prevalence of mood and/or anxiety disorders in Canada between self-report and administrative data.

Authors:  S O'Donnell; S Vanderloo; L McRae; J Onysko; S B Patten; L Pelletier
Journal:  Epidemiol Psychiatr Sci       Date:  2015-06-17       Impact factor: 6.892

Review 5.  Prospective: Is bipolar disorder being overdiagnosed?

Authors:  Tammas Kelly
Journal:  Int J Methods Psychiatr Res       Date:  2018-06-14       Impact factor: 4.035

Review 6.  The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research.

Authors:  Benjamin I Goldstein; Boris Birmaher; Gabrielle A Carlson; Melissa P DelBello; Robert L Findling; Mary Fristad; Robert A Kowatch; David J Miklowitz; Fabiano G Nery; Guillermo Perez-Algorta; Anna Van Meter; Cristian P Zeni; Christoph U Correll; Hyo-Won Kim; Janet Wozniak; Kiki D Chang; Manon Hillegers; Eric A Youngstrom
Journal:  Bipolar Disord       Date:  2017-09-25       Impact factor: 6.744

7.  Are we Overdiagnosing Bipolar Disorder?

Authors:  M S Reddy; Starlin M Vijay; Swetha Reddy
Journal:  Indian J Psychol Med       Date:  2017 Sep-Oct

8.  Polypharmacy-induced cognitive dysfunction and discontinuation of psychotropic medication: a neuropsychological case report.

Authors:  Jussi Valtonen; Mira Karrasch
Journal:  Ther Adv Psychopharmacol       Date:  2020-04-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.